Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

(2021) Stephen V. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis

(2021) Zhicheng Niu et al.   Annals of Translational Medicine

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

(2020) A.S. Mansfield et al.   ANNALS OF ONCOLOGY

Immunotherapeutic approaches for small-cell lung cancer

(2020) Wade T. Iams et al.   Nature Reviews Clinical Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer

(2020) Venu Madhav Konala et al.   ONCOLOGY

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

(2020) Francesco Facchinetti et al.   Cancers

Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer

(2020) Ting Zhou et al.   JAMA Network Open

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma

(2020) Hsiao-Ling Chen et al.   Cancers

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

(2019) T K Owonikoko et al.   ANNALS OF ONCOLOGY

1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

(2019) M Reck et al.   ANNALS OF ONCOLOGY

LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

(2019) L Paz-Ares et al.   ANNALS OF ONCOLOGY

MO3-9-5Subgroup Analysis of Japanese Patients in a Phase I/III Study of Atezolizumab in ES-SCLC (IMpower133)

(2019) Yosuke Kawashima et al.   ANNALS OF ONCOLOGY

LBA15Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

(2019) M Nishio et al.   ANNALS OF ONCOLOGY

LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

(2019) M Özgüroğlu et al.   ANNALS OF ONCOLOGY

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

(2019) L. Paz-Ares et al.   Journal of Thoracic Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

(2018) R Califano et al.   ANNALS OF ONCOLOGY

LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

(2018) T S K Mok et al.   ANNALS OF ONCOLOGY

A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)

(2016) L. Horn et al.   ANNALS OF ONCOLOGY

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) M. Fruh et al.   ANNALS OF ONCOLOGY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Small-cell lung cancer

(2011) Jan P van Meerbeeck et al.   LANCET

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

(2010) Lorraine C. Pelosof et al.   MAYO CLINIC PROCEEDINGS

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Bronchopulmonary neuroendocrine tumors

(2008) Bjorn I. Gustafsson et al.   CANCER